We hypothesize that potential compensation by AKT1 might explain why the CRIPSR KO AKT2 cells did not recapitulate the decreased subcutaneous tumor growth or the full prophylactic protection observed for the shRNA AKT2 KD cells, although we have not explicitly tested this hypothesis. This evidence concerns the gene AKT1 and neoplasm.